Meta-analysis of Interleukin-6 association with glycated hemoglobin (HbA1c) in pediatric type 1 diabetes mellitus
Keywords:
child, type 1 diabetes mellitus, interleukin-6, glycated hemoglobin a, meta-analysisAbstract
Background and aim: Type 1 diabetes mellitus (T1DM) is a chronic illness characterized by the destruction of insulin-secreting pancreatic β-cells. Poor glycemic control in T1DM patients, as reflected by glycated hemoglobin A1c (HbA1c) levels, increases pro-inflammatory cytokine levels, including interleukin-6 (IL-6). This could potentially lead to complications. Research on the correlation between IL-6 and HbA1c levels in children with T1DM has shown conflicting results.
Methods: A literature search was conducted on four databases for observational studies investigating the correlation between IL-6 and HbA1c levels in children with T1DM up to June 2024. A random meta-analysis model was performed. Fisher's r-to-z transformation was applied to standardize effect sizes for each correlation coefficient. Statistical significance was set at p <0.05 for all analyses.
Results: This study included 12 observational studies, six of which were cross-sectional. Published between 2003 and 2024, these studies involved 967 children. A pooled correlation coefficient value of 0.29 (95% CI: -0.04 - 0.56) with a p-value of 0.08 was obtained.
Conclusions: The correlation between IL-6 and HbA1c levels in children with T1DM showed a trend toward statistical significance. Although not statistically significant, this trend may still be important for understanding the inflammatory processes in T1DM. The weak correlation found between IL-6 and HbA1c levels in these children suggests that elevated pro-inflammatory cytokine concentrations were associated to poor glycemic control.
References
1. Bogdani M. Thinking outside the cell: a key role for hyaluronan in the pathogenesis of human type 1 diabetes. Diabetes. 2016;65(8):2105–14. doi: 10.2337/db15-1750
2. Shah AS, Nadeau KJ. The changing face of paediatric diabetes. Diabetologia. 2020;63(4):683–91. doi: 10.1007/s00125-019-05075-6
3. Libman I, Haynes A, Lyons S, Dabelea D, ISPAD Clinical Practice Consensus Guidelines 2022: definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2022;23(8):1160–74. doi: 10.1111/pedi.13454
4. Anand V, Li Y, Liu B, et al. Islet autoimmunity and HLA markers of presymptomatic and clinical type 1 diabetes: joint analyses of prospective cohort studies in Finland, Germany, Sweden, and the U.S. Diabetes Care. 2021;44(10):2269–76. doi: 10.2337/dc20-1836
5. Beyerlein A, Bonifacio E, Vehik K, et al. Progression from islet autoimmunity to clinical type 1 diabetes is influenced by genetic factors: results from the prospective TEDDY study. J Med Genet. 2018;56(9):602–5. doi: 10.1136/jmedgenet-2018-105532
6. Redondo MJ, Geyer S, Steck AK, et al. A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk. Diabetes Care. 2018;41(9):1887–94. doi: 10.2337/dc18-0087
7. Hundhausen C, Roth A, Whalen E, et al. Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci Transl Med. 2016;8(356):356ra119. doi: 10.1126/scitranslmed.aad9943
8. Lu J, Liu J, Li L, Lan Y, Liang Y. Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets. Clin Transl Immunology. 2020;9(3):e1122. doi: 10.1002/cti2.1122
9. Hammed IK, Rashid NF, Abed BA. Serum interleukin-6 level in children with type 1 diabetes mellitus. J Fac Med Baghdad. 2012;54(3):228–30. doi: 10.32007/jfacmedbagdad.543723
10. AboElAsrar MA, Elbarbary NS, Elshennawy DE, Omar AM. Insulin-like growth factor-1 cytokines cross-talk in type 1 diabetes mellitus: relationship to microvascular complications and bone mineral density. Cytokine. 2012;59(1):86–93. doi: 10.1016/j.cyto.2012.03.019
11. Heier M, Margeirsdottir HD, Brunborg C, Hanssen KF, Dahl-Jørgensen K, Seljeflot I. Inflammation in childhood type 1 diabetes; influence of glycemic control. Atherosclerosis. 2015;238(1):33–7. doi: 10.1016/j.atherosclerosis.2014.11.018
12. Abdel-Latif M, Abdel-Moneim AA, El-Hefnawy MH, Khalil RG. Comparative and correlative assessments of cytokine, complement and antibody patterns in paediatric type 1 diabetes. Clin Exp Immunol. 2017;190(1):110–21. doi: 10.1111/cei.13001
13. Al-Dubayee M, Babiker A, Alkewaibeen A, et al. Correlation analysis between cytokines' profile, autoimmune antibodies and the duration of type 1 diabetes: a case control study in a specialized children's centre in Riyadh. Int J Immunopathol Pharmacol. 2023;37:03946320231209821. doi: 10.1177/03946320231209821
14. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71
15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. doi: 10.1007/s10654-010-9491-z
16. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. doi: 10.1002/sim.1186
17. Fawaz L, Elwan AE, Kamel YH, Farid TM, Kamel A, Mohamed WA. Value of C-reactive protein and IL-6 measurements in type 1 diabetes mellitus. Arch Med Sci. 2009;5(3):383–90
18. Duque C, Joao MFD, da Cruz GA, et al. Microbiological, lipid and immunological profiles in children with gingivitis and type 1 diabetes mellitus. J Appl Oral Sci. 2017;25(2):217–26. doi: 10.1590/1678-77572016-0196
19. Fahad HM, Jassim AN, Nada SM. Investigation of inflammatory markers (IL-6 and hs-CRP) in type 1 diabetes patients. Int J Adv Res. 2014;2(3):572–9
20. Jain SK, Kannan K, Lim G, Matthews-Greer J, McVie R, Bocchini JA Jr. Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes. Diabetes Care. 2003;26(7):2139–43. doi: 10.2337/diacare.26.7.2139
21. Reis M, Teixeira A, Cardoso J, Borges T, Caldas Afonso A, Correia-Costa L. Association between proinflammatory cytokines and arterial stiffness in type 1 diabetic adolescents. J Pediatr Endocrinol Metab. 2024;37(5):405–12. doi: 10.1515/jpem-2023-0530
22. Wedrychowicz A, Dziatkowiak H, Sztefko K, Wedrychowicz A. Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2004;112(8):435–9. doi: 10.1055/s-2004-821189
23. Gouda W, Mageed L, El Dayem SMA, Ashour E, Afify M. Evaluation of pro-inflammatory and anti-inflammatory cytokines in type 1 diabetes mellitus. Bull Natl Res Cent. 2018;42:14. doi: 10.1186/s42269-018-0016-3
24. Ajie M, van Heck JIP, Janssen AWM, Meijer RI, Tack CJ, Stienstra R. Disease duration and chronic complications associate with immune activation in individuals with longstanding type 1 diabetes. J Clin Endocrinol Metab. 2023;108(8):1909–20. doi: 10.1210/clinem/dgad087
25. Chen Z, Li R, Xie Z, Huang G, Yuan Q, Zeng J. IL-6, IL-10 and IL-13 are associated with pathogenesis in children with Enterovirus 71 infection. Int J Clin Exp Med. 2014;7(9):2718–23
26. Hoffman RP, Dye AS, Huang H, Bauer JA. Glycemic variability predicts inflammation in adolescents with type 1 diabetes. J Pediatr Endocrinol Metab. 2016;29(10):1129–33. doi: 10.1515/jpem-2016-0139
27. Wang K, Ye F, Chen Y, et al. Association between Enterovirus infection and type 1 diabetes risk: a meta-analysis of 38 case-control studies. Front Endocrinol (Lausanne). 2021;12:706964. doi: 10.3389/fendo.2021.706964
28. Liu S, Hempe JM, McCarter RJ, Li S, Fonseca VA. Association between inflammation and biological variation in hemoglobin A1c in U.S. nondiabetic adults. J Clin Endocrinol Metab. 2015;100(6):2364–71. doi: 10.1210/jc.2014-4454
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sally Rizkita Lestari, Anang Endaryanto, Nur Rochmah, Citrawati Dyah Kencono Wungu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
